Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 23andMe, Inc.
After returning to the neuroscience space in the summer through a big-money deal with Alector, GlaxoSmithKline is setting up an institute with the University of Oxford that will target neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, frontal temporal dementia, ALS and pain.
Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance
In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.
With the acquisition of Lemonaid Health, at-home genome testing company 23andMe hopes to transform the primary care business with genetics insights.
According to Rock Health, 52 health-care focused SPACs are looking for targets. This comes as blank check companies are facing rising scrutiny by regulators.
- Laboratory Testing Services
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing